Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells by Geis, Franziska K. et al.
Geis et al. Retrovirology  (2017) 14:34 
DOI 10.1186/s12977-017-0358-1
RESEARCH
Potent and reversible lentiviral vector 
restriction in murine induced pluripotent stem 
cells
Franziska K. Geis1,2, Melanie Galla1,2, Dirk Hoffmann1,2, Johannes Kuehle1,2, Daniela Zychlinski1,2, 
Tobias Maetzig1,2, Juliane W. Schott1,2, Adrian Schwarzer1,2, Christine Goffinet3, Stephen P. Goff4,5,6 
and Axel Schambach1,2,7*
Abstract 
Background: Retroviral vectors are derived from wild-type retroviruses, can be used to study retrovirus-host interac-
tions and are effective tools in gene and cell therapy. However, numerous cell types are resistant or less permissive to 
retrovirus infection due to the presence of active defense mechanisms, or the absence of important cellular host co-
factors. In contrast to multipotent stem cells, pluripotent stem cells (PSC) have potential to differentiate into all three 
germ layers. Much remains to be elucidated in the field of anti-viral immunity in stem cells, especially in PSC.
Results: In this study, we report that transduction with HIV-1-based, lentiviral vectors (LV) is impaired in murine PSC. 
Analyses of early retroviral events in induced pluripotent stem cells (iPSC) revealed that the restriction is independ-
ent of envelope choice and does not affect reverse transcription, but perturbs nuclear entry and proviral integration. 
Proteasomal inhibition by MG132 could not circumvent the restriction. However, prevention of cyclophilin A (CypA) 
binding to the HIV-1 capsid via use of either a CypA inhibitor (cyclosporine A) or CypA-independent capsid mutants 
improved transduction. In addition, application of higher vector doses also increased transduction. Our data revealed 
a CypA mediated restriction in iPSC, which was acquired during reprogramming, associated with pluripotency and 
relieved upon subsequent differentiation.
Conclusions: We showed that murine PSC and iPSC are less susceptible to LV. The block observed in iPSC was CypA-
dependent and resulted in reduced nuclear entry of viral DNA and proviral integration. Our study helps to improve 
transduction of murine pluripotent cells with HIV-1-based vectors and contributes to our understanding of retrovirus-
host interactions in PSC.
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Background
In addition to their function as gene transfer vehicles, 
retroviral vectors can be utilized as tools to investigate 
specific vector-host interactions. Retroviral vectors are 
derived from their respective wild-type (wt) viruses by 
removal of nucleotide sequences in the RNA genomes, 
which are not essential for transgene delivery. Retrovi-
ral vectors are packaged into viral particles composed of 
structural and enzymatic proteins (Gag-Pol) and follow 
the natural course of the early retroviral life cycle. This 
includes cell entry, followed by a poorly-characterized 
uncoating process of the viral capsid, reverse transcrip-
tion (RT) of the viral RNA genome into double-stranded 
DNA, nuclear entry of the viral DNA and stable, proviral 
integration into the host genome [1].
In this study, we investigated vector-host interactions 
in pluripotent stem cells (PSC). These cells naturally exist 
in early embryonic development and give rise to all three 
germ layers. PSC represent the equivalent to the inner cell 
mass of the blastocyst and possess major differentiation 
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potential. Among PSC, induced pluripotent stem cells 
(iPSC) represent a prominent target cell type and cell 
source as they are easily generated by reprogramming of 
differentiated cells, a process mediated by ectopic expres-
sion of specific transcription factors [2]. After successful 
reprogramming, iPSC obtain full pluripotency capac-
ity and can differentiate into cells of all three germ lay-
ers in vitro as well as in vivo [3]. Therefore, iPSC display 
a suitable alternative to embryonic stem cells (ESC) for 
the study of cellular differentiation and disease modeling. 
Additionally, iPSC are promising resources for cell and 
gene therapy applications, e.g. innovative cell transplants 
mediated by retroviral gene transfer.
Retroviral vector application and their gene transfer 
efficiency are closely dependent on virus-host cell interac-
tions that either support or inhibit efficient infection. Ret-
roviral replication is supported by host co-factors, which 
are crucial for successful infection. A prominent retrovi-
ral host co-factor is cyclophilin A (CypA), which directly 
binds to an exposed loop of the human immunodeficiency 
virus type 1 (HIV-1) capsid protein [4, 5]. CypA was 
described to support early events of HIV-1 infection, such 
as uncoating and RT initiation [6, 7]. In addition, it was 
shown that the interaction of CypA with other host co-
factors determined the route of nuclear entry and led to 
alterations in integration site targeting [8]. Furthermore, 
capsid-associated CypA can shield HIV-1 against cellular 
recognition and prevent a type 1 interferon response [9]. 
In contrast, CypA-capsid binding can also inhibit HIV-1 
infectivity in a species-specific manner by increasing the 
sensitivity to certain restriction factors [9–11]. Restric-
tion factors are part of the cell autonomous immunity, 
are expressed by host cells and inhibit viral replication by 
inducing viral degradation, transcriptional silencing of 
integrated proviruses or initiation of anti-viral interferon 
responses. In this regard, previously identified restric-
tion factors in PSC include the Trim28/ZFP809 complex 
[12, 13] and YY1 [14]. Both factors target murine leuke-
mia virus (MLV) in murine ESC. However, the role of 
cell autonomous immunity in PSC is only incompletely 
understood and so far not described for HIV-1.
Here, we describe an HIV-1-based vector restriction 
found in iPSC as well as in ESC. Focusing on iPSC, we 
identified a CypA-dependent restriction mechanism that 
impaired nuclear entry and reduced proviral integra-
tion. The restriction could be decreased by application of 
high vector doses, by prevention of CypA binding to the 
HIV-1 capsid or by iPSC differentiation.
Results
Murine iPSC exhibit a potent block to HIV‑1‑based vectors
In this study we analyzed the susceptibility of murine iPSC 
for vectors derived from HIV-1 (LV; lentiviral vectors) or 
from Moloney MLV (GV; gammaretroviral vectors). Both 
retroviral vectors were designed with self-inactivating 
(SIN) architecture and expressed the enhanced green 
fluorescence protein (EGFP) reporter gene driven by a 
short version of the human elongation factor 1 alpha gene 
(EFS) promoter (Fig.  1a). If not indicated otherwise, we 
generated vector particles pseudotyped with the vesicular 
stomatitis virus glycoprotein (VSVg) envelope containing 
the vector RNA and the retroviral wt replication enzymes 
and structural proteins. Prior to iPSC transduction, vec-
tor supernatants were always titrated on permissive 
HT1080eCat cells in order to utilize comparable vector 
doses for following experiments. To compare retroviral 
transgene transfer into iPSC, LV and GV were applied 
to iPSC at defined multiplicities of infection (MOI). All 
iPSC used in this study were generated by ectopic expres-
sion of the octamer-binding transcription factor 4 (Oct4), 
sex determining region Y-box 2 gene (Sox2), Kruppel-like 
factor 4 (Klf4) and c-Myc in primary fibroblasts (Fig. 1b). 
A previously characterized and described iPSC clone 
(clone #2EX) was used throughout this study [15]. In this 
clone, the reprogramming cassette was excised by Flp 
recombinase to prevent interference with the integrated 
lentiviral reprogramming vector during PCR-based anal-
yses. Transduced cells were analyzed for EGFP and anti-
stage specific antigen marker 1 (SSEA1) (pluripotency 
marker in murine cells) co-expression by flow cytometry. 
Major differences in the susceptibility of murine iPSC 
for the tested retroviral vectors were observed. Notably, 
both GV and LV exhibited low transduction rates in iPSC 
using MOI 10 and 100 (Fig. 1c, left graph). However, LV 
transduction efficiency remained significantly reduced 
compared to GV at both MOI. Analyses of the mean vec-
tor copy number per cell (detecting EGFP) revealed sig-
nificantly less integrated vector copies in LV transduced 
iPSC indicating a pre-integration block (Fig.  1c, right 
graph). To exclude iPSC clone-specific abnormalities as 
the basis for the poor permissiveness to LV, we compared 
clone #2EX (excised reprogramming cassette) to a vari-
ety of iPSC clones generated by different reprogramming 
approaches and derived from various mouse strains. 
Additionally, we incorporated clones with non-excised 
reprogramming cassettes, including the parental clone 
#2 for direct comparison to the #2EX excised version. 
Remarkably, all tested iPSC clones demonstrated signifi-
cantly less susceptibility to LV transduction, suggesting 
that LV restriction is independent from the genetic back-
ground and the presence of the reprogramming cassette 
(Fig.  1d). To analyze whether naturally occurring PSC 
are susceptible to LV, we tested murine ESC. As similarly 
observed in iPSC, we measured decreased transduction 
rates for LV, in contrast to GV, caused by reduced integra-
tion events (Fig. 1e).
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LV restriction is observed exclusively in the pluripotent 
state of a cell
Next, we asked, if inhibition of LV gene transfer appears 
only in iPSC or can also be observed in the parental 
cells used for reprogramming or in iPSC differentiated 
progeny. In contrast to iPSC, the parental fibroblasts 
used for reprogramming, did not show a LV restric-
tion (Fig.  2a). To further test, whether LV restriction is 
directly correlated with the pluripotent state of the cells, 
we investigated if the differentiated progeny of iPSC 
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Fig. 1 Restriction of HIV-1-based vectors in murine iPSC. a Schematic overview of integrated LV and GV used in this study. Vectors contain two LTR 
with deleted U3 regions (∆U3, self-inactivating design), flanking an EGFP expression cassette driven by an EFS enhancer/promoter. SD splice donor, 
Ψ retroviral packaging signal, RRE rev responsive element, SA splice acceptor, cPPT central polypurine tract, wPRE woodchuck hepatitis virus post-
transcriptional regulatory element. b Scheme of reprogramming murine fibroblasts into iPSC by retroviral expression of Oct4, Sox2, Klf4 and c-Myc 
transcription factors. c iPSC transduced with three independently produced viral supernatants of LV and GV at an MOI of 10 and 100 (n = 3). Flow 
cytometry data of collected EGFP and SSEA1 (pluripotency marker) double positive cells are shown. NTD non-transduced control. One-way ANOVA 
with Tukey-Kramer post hoc test was used for statistical analyses. ns (not significant) p = 0.258; *** p ≤ 0.001 (left panel). LV (n = 6) or GV (n = 4) 
applied to iPSC at an MOI of 100. Mean vector copy numbers per cell were determined 6–8 days after transduction with SYBR Green-based quan-
titative real-time PCR, based on EGFP copies, and normalized to endogenous PTBP2 DNA copies. The unpaired t test with Welch’s correction was 
used for statistical analysis. * p = 0.017 (right panel). d LV and GV were applied to different iPSC clones at an MOI of 100. The percentage of EGFP and 
SSEA1 double positive cells was determined by flow cytometry. One-way ANOVA with Tukey-Kramer post hoc test was used for statistical analyses. 
#1 ** p = 0.004; #2, #2EX, #3 and #4 *** p ≤ 0.001. e LV and GV from three independently produced supernatants were applied to ESC at an MOI of 
10 and 100. Analyses were performed 6–8 days after transduction. The percentage of EGFP and SSEA1 double positive cells was measured by flow 
cytometry. One-way ANOVA with Tukey-Kramer post hoc test was used for statistical analyses. ns p = 0.660; *** p ≤ 0.001 (left panel). Mean vector 
copy numbers per cell were determined with SYBR Green-based quantitative real-time PCR, based on EGFP copies, and normalized to endogenous 
PTBP2 DNA copies and a plasmid standard (right panel)
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regained permissiveness to LV. We differentiated iPSC 
by withdrawal of the leukemia inhibitory factor (LIF) 
and cultured the cells in the absence of supporting feeder 
cells (Fig.  2b, upper panel). Differentiated cultures were 
transduced with LV or GV encoding DsRedExpress (LV.
DsRed and GV.DsRed). Transduced cells were stained 
with a green fluorescent SSEA1 antibody and live cell 
imaging was accomplished by fluorescence microscopy. 
Almost exclusively SSEA1 negative cells were transduced 
with LV, whereas SSEA1 and DsRedExpress double posi-
tive cells were observed more frequently after transduc-
tion with GV (Fig.  2b, lower panel). To better quantify 
transduction rates, we analyzed differentiated (SSEA1−) 
or remaining pluripotent (SSEA1+) cells by flow cytom-
etry. In line with the fluorescence microscopy approach, 
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Fig. 2 Restriction is observed at the pluripotent cell state. a LV were applied to C57BL/6 p14f/f adult fibroblasts (Ad fib) (n = 8) or C3H Mefs (n = 3) 
at an MOI of 10 and 100 (independently produced viral supernatants). The percentage of EGFP positive cells was determined by flow cytometry. 
NTD non-transduced control. b Scheme of iPSC differentiation by withdrawal of LIF and feeder cell co-cultivation (upper panel). Representative fluo-
rescence microscopy pictures of transduced differentiated cultures with LV.DsRed or GV.DsRed at an MOI of 100, SSEA1 live staining in green and an 
overlay of all channels are depicted (lower panel). c Differentiated cultures were transduced with LV (n = 5) and GV (n = 4) encoding EGFP at an MOI 
of 100 (independently produced viral supernatants). Pluripotent (SSEA1+) and differentiated (SSEA1−) cells were analyzed by flow cytometry. One-
way ANOVA with Tukey-Kramer post hoc test was used for statistical analyses. * p = 0.049; ns p = 0.706. d ECC transduced with LV (n = 3) or GV 
(n = 2) at an MOI of 10 and 100 (independently produced viral supernatants). The percentage of EGFP positive cells was analyzed by flow cytometry
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LV in contrast to differentiated SSEA1− cells (4.6 ± 1.6% 
vs. 19.8  ±  4.9%), while permissiveness of SSEA1+  and 
SSEA1− cells for GV particles was comparable 
(26 ± 13.7% vs. 33.5 ± 8.4%) (Fig. 2c). The impact of cell 
pluripotency on the LV block was further tested using 
embryonic carcinoma cells (ECC) as an additional pluri-
potent-like cell model [16]. Interestingly, ECC showed no 
LV restriction as observed in iPSC or ESC (Fig. 2d).
LV transduction rate in murine iPSC is enhanced by high 
vector doses and CSA treatment
It was previously shown that permissiveness of specific 
cell types to HIV-1 can be enhanced by altering the viral 
entry route [17, 18]. Therefore, we performed a side-by-
side comparison of envelope pseudotypes used for LV 
particle generation. We tested VSVg-pseudotyped LV 
(LV-VSVg) and included particles pseudotyped with gly-
coproteins derived from amphotropic (LV-Ampho) or 
ecotropic MLV (LV-Eco). While LV-VSVg enters cells via 
clathrin-mediated endocytosis [19], LV-Ampho employs 
cell membrane fusion and/or macropinocytosis [20, 21], 
and LV-Eco enters cells by calveolae-dependent endo-
cytosis and/or direct cell membrane fusion [22–24]. 
Although LV-VSVg, LV-Ampho and LV-Eco particles 
obtained comparable titers on permissive HT1080eCat 
cells (Fig.  3a, left graph), all vectors showed very low 
transduction rates of iPSC (less than 1%) at an MOI of 
10 (Fig.  3a, right graph). Previous work demonstrated 
the possibility to apply high virus doses to overcome 
a restriction factor-mediated block [25–28]. Thus, we 
transduced murine iPSC with LV at increasing MOI. 
Transduction rates were enhanced from 0.84  ±  0.45% 
(MOI 10) to 25.83 ± 2.57% (MOI 2000) (Fig. 3b). Despite 
a 30-fold increase with the highest vector dose, the 
majority of iPSC remained untransduced, suggesting rel-
atively inefficient abrogation of LV restriction. Next, we 
performed pre-transduction (Pre-Td) experiments fol-
lowed by a second transduction to investigate a potential 
increase in transducability in a second round of transduc-
tion. This method is frequently used to provide evidence 
for a saturable restriction factor, when the factor can be 
abrogated at a certain MOI of the restricted incoming 
viral particles [28, 29]. Pre-Td was conducted with DsRe-
dExpress encoding LV.DsRed and GV.DsRed at an MOI 
of 1000. GV.DsRed Pre-Td served as a control to exclude 
common cellular defense mechanisms after transduction 
with high MOI. Following published protocols, a second 
transduction was then performed with EGFP-encoding 
LV, at an MOI of 100, 6 h after Pre-Td [25, 28]. Although 
having conducted successful Pre-Td (Fig. 3c, right graph), 
Pre-Td resulted in no beneficial effect on LV transduc-
tion rates (Fig. 3c, left graph). Next, we tested the small 
molecules MG132 and cyclosporine A (CSA), which were 
previously described to enhance lentiviral transduction 
and counteract lentiviral restriction [11, 30–33]. Dose 
escalation experiments (using 0.05–0.4 µM) with the pro-
teasome inhibitor MG132 failed to increase LV transduc-
tion rates in iPSC (Fig. 3d). Of note, at doses ≥ 0.2 µM, 
we observed a cytotoxic effect of the drug, resulting in 
decreased cell numbers as well as in increased Annex-
inV and PI positive cells (see Additional file 1). To inves-
tigate if abrogation of the CypA-capsid interaction by 
CSA treatment could circumvent the restriction, as this 
has been described in other cell types in previous studies 
[34–37], we transduced iPSC in the presence or absence 
of different CSA doses. Strikingly, CSA treatment dur-
ing transduction significantly enhanced LV transduction 
rates in a dose-dependent manner (Fig. 3e, left graph). In 
contrast, CSA had no statistically significant effect on GV 
transduction rates (Fig. 3e, right graph). Of note, while no 
apoptosis or cell death was observed for any tested CSA 
concentration, decreased cell numbers were observed 
with 20  µM CSA (see Additional file  2). Since doses 
≤ 10 µM did not affect cell numbers, a concentration of 
10 µM CSA was chosen for all further experiments.
CypA‑capsid interaction mediates LV restriction in iPSC
To characterize the dependency of CSA on the time of 
its addition, we conducted a kinetic study and treated 
iPSC with CSA at different time points prior to and dur-
ing transduction. LV transduction without CSA treat-
ment contained equal amounts of DMSO as a solvent 
control. Interestingly, the strongest CSA effect on LV 
transduction rate enhancement in iPSC was achieved 
when adding CSA before (−0.5 h) or at the time of trans-
duction (0  h) (Fig.  4a). Nevertheless, CSA addition still 
had a significant effect on iPSC susceptibility to LV even 
when applied 12 h after retroviral vector application. To 
test whether CypA-capsid interaction mediates the LV 
restriction or if CSA acts through different mechanisms, 
we prevented CypA binding to the HIV-1 capsid by 
using specific CypA-independent HIV-1 capsid mutants. 
We compared HIV-1 wt capsid and the mutant cap-
sid variants G89V, P90A, H2.1 and A88T for their abil-
ity to transduce iPSC. The G89V, P90A and A88T capsid 
mutants harbor a point mutation causing a single amino-
acid change in the CypA binding loop of the HIV-1 
capsid, preventing CypA binding to the capsid [36, 38]. 
Of note, the A88T mutant was shown to prevent bind-
ing of CypA and also the myxovirus resistance 2 (Mx2) 
protein, which was identified as an HIV-1 restriction fac-
tor [34–36]. The H2.1 mutant contains a substitution of 
the equivalent CypA binding loop sequences of HIV-1 
to HIV-2, which does not bind CypA [39]. Remarkably, 
all CypA-independent capsid mutants exhibited clearly 
improved LV transduction rates (Fig. 4b). In addition, we 


















































































































































































































Fig. 3 Restriction is circumvented by high MOI or CSA treatment. a LV particles pseudotyped with VSVg (LV-VSVg, n = 3), amphotropic (LV-Ampho, 
n = 3) or ecotropic MLV envelopes (LV-Eco, n = 2) were titrated on permissive HT1080eCat fibroblasts and titers were determined by flow cytom-
etry as transducing units per mL (TU/mL from independently produced viral supernatants) (left panel). The different pseudotyped LV particles were 
applied to iPSC at an MOI of 10 and the percentage of EGFP and SSEA1 double positive cells was assessed by flow cytometry (right panel). b iPSC 
were transduced at indicated MOI. EGFP and SSEA1 double positive cells from independent replicates were collected by flow cytometry. MOI 10, 
n = 5; MOI 100, n = 4; MOI 250, n = 5; MOI 500, n = 5; MOI 1000, n = 5; MOI 2000, n = 4. c Pre-transduction (Pre-Td) experiments in iPSC were per-
formed by Pre-Td with LV.Red or GV.Red at an MOI of 1000 (n = 3; independently produced viral supernatants) followed by a second transduction 
with LV at an MOI of 100, 6 h after Pre-Td. Data of the second transduction are shown relative to no Pre-Td (left panel). Transduction of LV.Red and 
GV.Red are shown as the Pre-Td control (right panel). d iPSC transduced with LV at an MOI of 100 in the presence of MG132 at indicated concentra-
tions. Data from 3 independently produced viral supernatants were determined by flow cytometry. e LV (left graph) or GV (right graph) were applied 
to iPSC at an MOI of 100 in the presence of CSA at the indicated concentrations. Data from 3 to 4 independently produced viral supernatants were 
determined by flow cytometry. One-way ANOVA with Dunnett post hoc test was used for statistical analyses. LV 0 versus 10, *** p ≤ 0.001; LV 0 
versus 20, ***p ≤ 0.001; GV 0 versus 10, ns p = 0.999; GV 0 versus 20, ns p = 0.112
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tested the capsid mutant N74D. N74D harbors a point 
mutation, which prevents binding of cleavage and poly-
adenylation specific factor 6 (CPSF6) to the capsid, binds 
CypA to a lower extent than wt capsids and favors a dif-
ferent nuclear entry route compared to the wt capsid [8, 
40, 41]. It was previously reported that the early steps of 
infection by the N74D capsid mutant virus were inhib-
ited prior to RT in macrophages [42]. Importantly, we 
did not observe this effect in iPSC, since late RT products 
using N74D mutant and wt capsid were comparable (see 
Additional file 3). Interestingly, the N74D capsid mutant 
did not improve LV transduction (Fig. 4b). To investigate 
whether the differences in LV transduction efficiencies 
observed between iPSC and differentiated cell types were 
due to different intrinsic CypA protein levels, Western 
blot analyses were used to compare CypA levels in iPSC 
with their parental fibroblasts and other primary fibro-
blasts. iPSC displayed comparable CypA levels to the 
permissive Mefs, indicating that LV restriction was not 
due to altered CypA protein expression (Fig. 4c).
Low efficiency of LV transduction in iPSC is associated 
with reduced levels of 2‑LTR circles and proviral DNA 
integration
We observed strongly reduced vector copies in LV trans-
duced iPSC (Fig.  1c). To characterize the observed LV 
restriction in greater detail and to identify the step of the 
early retroviral life cycle affected in iPSC, we analyzed 
the generation of viral intermediates between cellular 
entry and integration. iPSC were transduced with LV at 
an MOI of 10 and emerging RT products were analyzed 
with TaqMan-based quantitative real-time PCR at dif-
ferent time points. CSA treated cells served as a control 
for effective LV transduction. RT product levels were 
normalized to endogenous polypyrimidine tract bind-
ing protein 2 (PTBP2) DNA copies. Heat-inactivated 
supernatants (plasmid ctrl) served as a control for plas-
mid contamination in the viral vector preparations and 
DMSO as the solvent control for CSA treated cells. No 
differences were detected in early RT (Fig. 5a) or late RT 
product levels (Fig. 5b) when comparing DMSO to CSA 
treated iPSC. To analyze whether the reverse transcribed 
viral DNA is imported into the nucleus, we investigated 
the levels of 2-LTR circles, which are considered as a 
marker for nuclear entry and are formed in the nucleus 
by the host cell repair machinery [43–45]. The levels of 
2-LTR circles were analyzed by TaqMan-based quan-
titative real-time PCR (normalized to PTBP2). Primers 
and probes were designed to detect the LTR-LTR junc-
tion region to avoid detection of LV autointegration 
[45]. In DMSO treated samples, 2-LTR circles were sig-
nificantly reduced at 6 and 12 h after vector application 
when compared to CSA-treated cells (Fig. 5c). Next, we 
included the integrase inhibitor Raltegravir to impede 
b ca
CSA treatment 




































































Fig. 4 CypA-capsid interaction mediates LV restriction independent from CypA expression. a iPSC were transduced with LV at an MOI of 100 in 
the presence of 10 µM CSA. CSA was added at indicated time points prior to or during transduction. The percentage of EGFP and SSEA1 double 
positive cells from 3 independently produced viral supernatants were assessed by flow cytometry. Repeated measures one-way ANOVA with 
Dunnett post hoc test was used for statistical analyses. *** p ≤ 0.001; ** p = 0.003. b Transduction of iPSC with LV, harboring wt or mutated HIV-1 
capsids. The percentages of EGFP and SSEA1 double positive cells were quantified by flow cytometry (wt n = 9, wt + CSA n = 9; G89V n = 3; P90A 
n = 3; H2.1 n = 3; A88T n = 5; independently produced viral supernatants). One-way ANOVA with Dunnett post hoc test was used for statistical 
analyses. wt versus wt + CSA, *** p ≤ 0.001; wt versus G89V, * p = 0.014; wt versus P90A, ns p = 0.066; wt versus H2.1, *** p ≤ 0.001; wt versus A88T, 
** p = 0.002; wt versus N74D, ns p = 0.9996. c Western blot analysis showing cellular CypA protein levels in iPSC, C57BL/6 p14f/f adult fibroblasts 
and CF1-Mefs. The percentage of the CypA/Erk2 ratio is depicted for each cell type relative to iPSC
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integration and to determine the amount of 2-LTR cir-
cles in the presence or absence of CSA. The inhibition 
of integration by Raltegravir led to significantly higher 
levels of 2-LTR circles in CSA treated cells, but only a 
minor increase of 2-LTR circles in DMSO treated cells 
(see Additional file 4A). Interestingly, treatment of trans-
duced iPSC with Raltegravir and CSA compared to 
Raltegravir alone led to significantly elevated 2-LTR cir-
cle levels. These findings further strengthen the hypoth-
esis that nuclear entry of LV was impaired in iPSC. 
Strikingly, CSA treatment also significantly increased 
integrated vector copy numbers (see Additional file 4B). 
Transduction of Mefs treated under identical conditions 
served as permissive controls and showed no major 
effect of CSA on transduction rates in these cells (see 
Additional files 4A and B). To determine the time point 
of integration, we analyzed samples from Fig. 5a–c with 
the B1-LTR PCR, which is the mouse equivalent to the 
human Alu-LTR PCR. Briefly, proviral integrants were 
detected with primers detecting the LTR and the B1 
repetitive elements in the genome (first stage of PCR), 
followed by a nested LTR amplification step (second 
stage PCR). Proviral integration started at 12 h and 
reached a plateau 24 h after vector application, with no 
major differences thereafter (as measured at 48 h and a 
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Fig. 5 Nuclear entry and integration of LV is reduced in iPSC. iPSC were transduced at an MOI of 10 (with independently produced viral superna-
tants as indicated) in the presence of 10 µM CSA or an equal volume of DMSO as solvent control. Cells were washed 6 h after vector application and 
harvested at indicated time points. Data are shown relative to the 24 h time point of LV transduced cells treated with CSA. Samples were analyzed 
for early RT (n = 3) (a), late RT products (n = 3) (b), 2-LTR circles (n = 6; * p = 0.030; ** p = 0.005) (c) and proviral vector copies (n = 3; ** p = 0.004; 
*** p ≤ 0.001) (d). RT products and 2-LTR circles were evaluated with TaqMan-based quantitative real-time PCR with the 2−Ct method, normal-
ized to endogenous PTBP2 copies. Proviral vector copies were determined by B1-LTR PCR and obtained values were corrected for plasmid contami-
nation. Repeated measures one-way ANOVA with Tukey-Kramer post hoc test was used for statistical analyses. NTD non-transduced control; plasmid 
ctrl plasmid contamination control
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Discussion
In this study, we transduced iPSC in order to investigate 
vector-host interactions in the early retroviral life cycle in 
pluripotent cell types. Our results revealed that murine 
iPSC exhibited a potent restriction against HIV-1-based 
vectors, which was observed after reprogramming 
fibroblasts into the pluripotent state. Dissecting retro-
viral intermediates to localize LV restriction revealed 
functional RT (including early and late RT products), 
impaired nuclear entry (as measured by 2-LTR circle 
formation) and reduced proviral integration (as deter-
mined by mean vector copy number per cell and provi-
ral integrates). Transduction rates were improved by the 
use of high vector doses, prevention of CypA binding to 
HIV-1 capsid (by CSA or using CypA-independent cap-
sid mutants) or differentiation into iPSC progeny (Fig. 6).
The fact that efficiently reverse transcribed proviral 
DNA of LV failed to integrate into the chromatin of iPSC 
(Figs. 1c, 5d) suggests inefficient cytoplasmic trafficking, 
nuclear entry and/or integration. Our 2-LTR circle analy-
ses at different time points after transduction (6, 12, 24, 
48  h) revealed significantly reduced levels in untreated 
compared to CSA-treated cells (Fig. 5c). In addition, cells 
treated with the CSA/Raltegravir combination exhibited 
a pronounced increase of 2-LTR circles when compared 
to cells treated with Raltegravir application alone (see 
Additional file  4A). These findings clearly support that 
the mechanism responsible for the LV restriction in iPSC 
involved inefficient nuclear entry and that CSA relieved 
this hindrance. This could be explained by unproductive 
nuclear entry due to misdirected cytoplasmic trafficking 
to the nucleus, trapping of the PIC or impaired transloca-
tion into the nucleus. Alternatively, it is possible that, in 
addition to the nuclear entry block, there is an intranu-
clear block (e.g. caused by altered nuclear trafficking or 
perturbed integration), which is supported by different 
ratios of 2-LTR circles and proviral integration levels (see 
Additional file 4A and Fig. 5d). However, we hypothesize 
that the main block affects the nuclear entry step.
We identified the CypA-capsid interaction as a key 
event that mediated the restriction. Prevention of CypA-
capsid interaction by CSA or specific CypA-independent 
capsid mutants led to a significant increase in trans-
duction (Figs.  3e, 4b). Our data provide evidence that 
this interaction is most crucial relatively early after cell 
entry, but we also observed supportive effects of CSA 
at the latest time point measured (12 h) (Fig. 4a). Inter-
estingly, CypA expression levels were comparable in 
restricted iPSC and permissive cells, thus there was no 
correlation between CypA levels and the block (Fig. 4c). 
Furthermore, we were unable to saturate the block by 
pretransduction with high doses (MOI 1000) of LV in our 
abrogation experiments  (Fig.  3c). Potential explanations 
for the lack of an abrogation phenotype include: (I) even 
higher concentrations are needed to saturate the poten-
tial factor; (II) the block is not saturable; (III) using our 
doses, other essential cellular pathways and receptors are 
blocked and are not recycled in a timely manner in the 
6 h time window before the second transduction.
The restriction was relieved by use of CypA-independ-
ent capsid mutants (P90A, G89V, H2.1, A88T) (Fig. 4b). 
In contrast, the N74D capsid mutant, which binds CypA 
to a lower extent than the wt capsid, revealed no ben-
eficial effect on transduction [42]. This suggests that 
the amount of capsid-bound CypA is important for the 












Fig. 6 Schematic overview of LV restriction and strategies to improve murine iPSC transduction. Primary fibroblasts of murine origin were efficiently 
transduced with LV. After reprogramming, iPSC exhibited a potent LV restriction phenotype, which was decreased by high vector amounts, HIV-1 
CypA-independent capsid mutants, treatment with CSA during transduction or iPSC differentiation
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the capsid mutants P90A and G89V utilize different 
nuclear entry routes compared to wt capsid [8]. We can 
therefore envision that, in addition to avoiding binding of 
CypA molecules to the capsid, also the different nuclear 
entry routes could play a role in relieving the restrictive 
phenotype of LV in iPSC.
In addition to a potential restriction factor, the block 
may also be explained by the lack of a necessary host co-
factor. Thus, we performed a detailed microarray analysis 
of different iPSC clones and their parental fibroblasts and 
compared expression of previously reported HIV-1 host 
co-factors for nuclear entry and integration as well as of a 
set of murine nucleoporins (see Additional file 5). When 
compared to adult fibroblasts, iPSC exhibited similar or 
even higher expression levels of examined nucleoporins 
and important host co-factors for nuclear entry and inte-
gration. This suggests that differences in expression levels 
of the analyzed HIV-1 host co-factors and nucleoporins 
do not contribute to the underlying mechanism of the 
observed block.
As previously described, somatic and pluripotent 
stem cells evolved anti-viral defense mechanisms 
[12, 14, 31, 46–48]. The novel LV block we identified 
in iPSC is acquired during the process of reprogram-
ming and relieved upon differentiation (Fig.  2a–c). 
In our experiments ESC and iPSC exhibited similarly 
low LV transduction rates and integration events com-
pared to GV (Fig. 1c, e). In contrast, this phenomenon 
is less pronounced in ECC (Fig.  2d) [16]. This might 
be explained by the fact that ECC are supposed to rep-
resent a more differentiated status compared to PSC, 
including iPSC and ESC. Thus, we hypothesize that 
the LV restriction in iPSC may be associated with the 
pluripotent state.
Although, murine cells are not the natural host for 
HIV-1, lentiviruses were isolated from several species 
other than primates and the CypA-capsid interaction was 
also discovered to be highly conserved [49]. Moreover, 
the presence of endogenous lentiviruses in the genomes 
of a variety of different species demonstrates that lenti-
viruses are more widespread than previously assumed. 
Therefore, an active lentiviral defense mechanism in 
murine PSC is imaginable. Likewise, much remains to be 
discovered regarding anti-viral defense mechanisms in 
stem cells, especially in PSC. This knowledge can help to 
develop more efficacious anti-viral treatments in order to 
modulate cell autonomous immunity, and also increase 
gene transfer efficiencies for studies in basic biology 
and therapeutic approaches. Our findings document the 
characteristics of the restriction against HIV-1 found in 
PSC and contribute to our understanding of HIV-1-host 
interactions.
Conclusions
We identified CypA as a key player in LV restriction in 
iPSC and discovered impaired nuclear entry and proviral 
integration as underlying mechanisms for low transduc-
tion rates. To the best of our knowledge an HIV-1 block 
in PSC has not been previously described. Furthermore, 
the restriction was not observed in parental fibroblasts 
or differentiated iPSC progeny, which suggests that LV 
restriction is acquired through reprogramming into the 
pluripotent state. While our investigation demonstrated 
a novel HIV-1 restriction in murine PSC, it remained 
unclear whether the restriction is caused by a restric-
tion factor or the absence of an essential host co-factor. 
While CypA was previously described to either support 
or inhibit wt HIV-1 infection in a cell type-dependent 
manner, the CypA-capsid interaction, we identified to be 
responsible for the restriction in iPSC, differs from pre-
viously described studies and clearly contributes to our 
understanding of the anti-viral activity in PSC.
Methods
Retroviral vector plasmids
Lentiviral vector plasmids pRRL.PPT.EFS.EGFP.pre [50–
52] and pRRL.PPT.SFFV.DsRedExpress.pre [53] were 
referred to as LV and LV.DsRed, respectively. Gammaret-
roviral vectors pSERS11.EFS.EGFP.pre [52] and pSF91.
DsRedExpress [53] were termed GV and GV.DsRed. 
Except for the LTR-driven GV.DsRed, all vectors had 
SIN designs with deletions of the viral U3 regions (∆U3), 
instead containing the internal EFS promoter (short ver-
sion/250  bp fragment of promoter/enhancer sequences 
from the human elongation factor 1 alpha gene) or, for 
LV.DsRed, the SFFV promoter (promoter/enhancer 
sequences from spleen focus forming virus). For repro-
gramming, the lentiviral “4-in-1” construct pRRL.PPT.
SF.hOKSMco.id.Tom.pre.F+F3, co-expressing codon-
optimized versions of the transcription factors Oct4, 
Klf4, Sox2 and wt c-Myc, was used [15, 54]. The construct 
contained heterospecific FRT sites (F and F3) to allow Flp 
recombinase-mediated excision of the reprogramming 
cassette [15, 55].
Cells and cultivation
Human 293T (embryonic kidney cell line) [56], human 
HT1080eCat (fibroblast cell line HT1080 [57] express-
ing the murine ecotropic receptor mCAT-1 [53]) and 
the murine ECC line F9 (kindly provided by S. P. Goff, 
Columbia University  Medical Center, New York, NY, 
USA) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (Biochrom GmbH, Berlin, Germany) 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (GE Healthcare Europe GmbH, Freiburg, 
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Germany), 100 U/mL penicillin, 100  µg/mL streptomy-
cin and 1  mM sodium pyruvate (all from PAN-Biotech, 
Aidenbach, Germany). CF-1 Mefs (MTI Global Stem, 
Gaithersburg, MD, USA) and C3H Mefs (kindly provided 
by T. Cantz, Hannover Medical School, Hannover, Ger-
many) as well as freshly isolated murine adult fibroblasts 
(C57BL/6 p14f/f ) were grown in low glucose DMEM 
(PAN-Biotech) supplemented with 15% heat-inactivated 
FBS, 100 U/mL penicillin, 100  µg/mL streptomycin, 
2 mM l-glutamine, 1% MEM non-essential amino acids 
solution (Gibco Life Technologies GmbH, Darmstadt, 
Germany) and 100  µM beta-mercaptoethanol (Sigma-
Aldrich, Munich, Germany) on gelatin pre-coated (0.1% 
gelatin in phosphate buffered saline (PBS)) wells or flasks. 
PSC were co-cultured with irradiated (30 Gy) C3H Mefs 
in ESC medium composed of Knockout DMEM (Gibco 
Life Technologies) with 15% ESC-tested and heat-inacti-
vated FBS (GE Healthcare Europe GmbH), 2 mM l-glu-
tamine, 100 U/mL penicillin, 100  µg/mL streptomycin, 
1% MEM non-essential amino acids, 100  µM beta-mer-
captoethanol and  103 U/mL LIF (kindly provided by the 
Department of Technical Chemistry, Leibniz University 
Hannover, Hannover, Germany). The following murine 
PSC were used in this study: iPSC clone #1 (C57BL/6 
mouse strain), clones #2, #2EX (excised reprogramming 
cassette) and #3 (C57BL/6 p14f/f, wt version without 
conditional knockout of the p14 gene, reprogrammed 
from adult fibroblasts, mice kindly provided by D. Kotlarz 
and C. Klein, Ludwig  Maximilian University, Munich, 
Germany), clone #4 (reprogrammed from C3H Mefs) and 
ESC (C57BL/6 mouse strain, kindly provided by I. Prinz, 
Hannover Medical School).
Retroviral particle production
One day before transfection, 5  ×  106 293T cells were 
seeded per 10-cm dish. Transfection was performed 
based on the calcium phosphate precipitation method 
assisted by 25  µM chloroquine (Sigma-Aldrich). For LV 
or LV.DsRed, packaging cells were co-transfected with 
5  μg LV plasmid, 5  μg pRSV-Rev (kindly provided by 
T. Hope, Northwestern University, Chicago, IL, USA), 
1.5 μg pMD.G (VSVg) [58], 12 μg wt pcDNA3.gp.4xCTE 
(HIV-1 Gag-Pol) [59] or CypA-independent capsid 
mutant Gag-Pol P90A, G89V, A88T or H2.1 or the N74D 
mutant [36, 38, 39, 41]. Mutations were introduced by 
overlap extension PCR and confirmed by sequencing. 
For production of LV-Ampho(tropic) and LV-Eco(tropic) 
particles, 2  μg ecotropic [60] or 2  μg amphotropic [61] 
MLV envelope encoding plasmids were used. To package 
VSVg pseudotyped GV or GV.DsRed particles, 5 μg GV 
plasmid, 7 μg pcDNA3.MLV.GP (MLV Gag-Pol) [59] and 
1.5  μg pMD.G were co-transfected. Supernatants were 
harvested 36 and 48 h after transfection, filtered through 
0.22  μm pore-size-filters and concentrated (100×) by 
ultracentrifugation (2 h, 82,740×g, 4  °C) (SW32Ti rotor; 
Beckman Coulter GmbH, Krefeld, Germany). Viral pel-
lets were resuspended in ESC medium and stored in ali-
quots at −80 °C until further usage.
Retroviral particle titration and transduction
One day before titration of vector supernatants, 7 × 104 
HT1080eCat cells were seeded per well of a 12-well plate. 
The next day, the culture medium was removed and serial 
dilutions of vector supernatants were added to the cells. 
Viral transduction of cells was performed in the presence 
of 4 µg/mL protamine sulfate and spin-inoculation (1 h, 
863×g, 37  °C). Three days after transduction, the per-
centage of fluorescent cells was analyzed by flow cytom-
etry. Vector particle titers were calculated only including 
samples with <  30% transduced cells to avoid multiple 
proviral integration events per cell and false titer esti-
mation. Mefs (3 ×  104 cells per well of a 12-well plate) 
or ECC (5 ×  104 cells per well of a 12-well plate) were 
seeded the day before transduction. Specific amounts of 
vector particles per cell, referred to as MOI, were applied 
and cells were treated as described above for titration. 
PSC were transduced in single cell suspension and sepa-
rated with 0.5% Trypsin-EDTA in PBS (Gibco Life Tech-
nologies GmbH) on the day of transduction. Afterwards, 
PSC were centrifuged (138×g, 5  min) and depleted 
from feeder cells. Depletion was performed by incubat-
ing the cells on a 15-cm plate (40  min, 37  °C, 5%  CO2) 
to separate the faster attaching feeder from PSC. After 
applying vector supernatants at specific MOI to 3 × 104 
cells (12-well plate) and adding 4 µg/mL protamine sul-
fate, a spin-inoculation step (1  h, 863×g, 37  °C) and an 
incubation step (1 h,  37  °C, 5%  CO2) were performed, 
before PSC were added to feeder cells. The next day, 
PSC had attached to the feeder cell layer, and the virus-
containing medium was replaced by fresh ESC medium. 
For small molecule supplemented transductions, cells 
were incubated 30 min prior to and during transduction 
with indicated concentrations of CSA (Sigma - Aldrich), 
MG132 (Calbiochem/Merck Millipore, Darmstadt, Ger-
many), Nevirapine (Sigma-Aldrich) or Raltegravir (Santa 
Cruz Biotechnology, Dallas, TX, USA). Depending on 
the cell type and experiment, cells were processed by 
flow cytometry 2  days (differentiated cultures), 3  days 
(HT1080eCat titration, C3H Mefs), 5–8 days (adult fibro-
blasts, ESC, ECC, iPSC) or at indicated time points after 
transduction.
Reprogramming murine primary fibroblasts to iPSC
Murine fibroblasts from the indicated mouse strains were 
reprogrammed and characterized as previously described 
by our group [15, 54].
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Differentiation of iPSC
To induce differentiation, iPSC were depleted from 
feeder cells, seeded in gelatin pre-coated (0.1% gelatin 
in PBS) 12-well plates (5 × 104 per well) and cultured in 
ESC medium without LIF and feeder cells. Medium was 
exchanged daily and cells were split in the range of 1:5–
1:20 on days 3–4 and 5–6. Prior to transduction of differ-
entiated cultures, cells were stained for SSEA1 expression 
and analyzed by flow cytometry to investigate their stem 
cell status. Differentiated cultures were transduced with 
retroviral particles (MOI 100) encoding EGFP or DsRe-
dExpress 6–9  days after starting differentiation. Cells 
transduced with DsRedExpress encoding vectors were 
additionally stained with Stain Alive SSEA1 Antibody 
DyLight 488 according to the manufacturer’s protocol 
(Stemgent, Cambridge, MA, USA) and analyzed by fluo-
rescence microscopy 2  days after transduction. Pictures 
were acquired with Axio Observer Z1 (Carl Zeiss AG, 
Jena, Germany) using Zeiss filter sets 43 (DsRedExpress) 
and 38 (DyLight 488) and AxioVision 4.8 software. Cells 
transduced with EGFP encoding vectors were analyzed 
by flow cytometry 2 days after transduction.
Flow cytometry
Cells were harvested and subsequently analyzed by flow 
cytometry (FACS Calibur, Becton-Dickinson, Heidelberg, 
Germany) using FlowJo software (Tree Star Inc, Ashland, 
OR, USA). In addition, PSC or differentiated cultures 
were stained with an Alexa 647 labeled SSEA1 antibody 
(1.5 ng per sample, 30 min, 4 °C) (eBioscience, San Diego, 
CA, USA). Samples were pre-gated for viable cells. Data 
from total viable cell populations with at least 50% SSEA1 
positive cells were included in the analyses. The range 
of SSEA1 positive cells constituted mostly 70–100% 
throughout the study. The 70–100% range derives from 
differences between independent transduction experi-
ments, but there were equivalent amounts of SSEA1 pos-
itive cells within each experiment. Cells, double positive 
for SSEA1 and EGFP, are shown in the graphs.
SYBR Green‑based quantitative real‑time PCR for detection 
of mean vector copy number per cell
iPSC were transduced with LV and GV and DNA was iso-
lated 6–8 days after transduction. Vector copies per cell 
shown in Fig. 1c, e and Additional file 4B were determined 
by SYBR Green-based quantitative real-time PCR based 
on EGFP copies (Applied Biosystems, Darmstadt, Ger-
many) using the QuantiTect SYBR-Green PCR Kit (Qia-
gen, Hilden, Germany) normalized to endogenous PTBP2 
(EGFP for: 5′CTATATCATGGCCGACAAGCAGA3′, rev: 
5′GGACTGGGTGCTCAGGTAGTGG3′; PTBP2 for: 
5′GTCTCCATTCCCTATGTTCATGC3′, rev: 5′GTTCC 
CGCAGAATGGTGAGGTG3′). Master Mix preparation 
and PCR were performed as instructed by the manufac-
turer. Quantification of the mean vector copy number per 
cell were determined based on the comparative  2−∆∆Ct 
method and based on a reference plasmid containing 
EGFP and PTBP2 sequences [62–64].
Analysis of RT products, 2‑LTR circles and proviral 
integration by TaqMan‑based quantitative real‑time PCR
Vector supernatants were applied (MOI 10) to iPSC and 
CF-1 Mefs and remaining vector particles were removed 
by washing the cells twice with PBS 6  h after transduc-
tion. Cells were harvested at indicated time points. To 
test for plasmid contamination of vector supernatants, 
equivalent volumes of vector supernatants were heat-
inactivated at 65  °C for 1  h and included in the analy-
ses (plasmid ctrl). DNA isolation was performed with 
the QIAamp DNA Blood Mini Kit (Qiagen) according 
to the manufacturer’s instructions. For TaqMan-based 
quantitative real-time PCR (Applied Biosystems), RT 
products were analyzed for early RT products (strong-
stop DNA, for: 5′GCCTCAATAAAGCTTGCCTTGA3′, 
rev: 5′TGACTAAAAGGGTCTGAGGGATCT3′, probe: 
5′AGAGTCACACAACAGACGGGCACACACTA3′), 
late RT products (U5/downstream PBS, for: 5′TA 
GTGTGTGCCCGTCTGTTG3′, rev: 5′GAGTCCTG 
CGTCGAGAGAG3′, probe: 5′TCCCTCAGACCCT 
TTTAGTCA3′) and 2-LTR circles (junction, for: 
5′TAGTGTGTGCCCGTCTGTTG3′, rev: 5′CAGAGA 
GACCCAGTACAAGC3′, probe: 5′CTCTAGCAGTAAC 
TGGAAGGGCT3′). PTBP2 served as a housekeeping 
control (for: 5′TCTCCATTCCCTATGTTCATGC3′, 
rev: 5′GTTCCCGCAGAATGGTGAGGTG3′, probe: 
5′ATGTTCCTCGGACCAACTTG3′). RT products 
were relatively quantified using the comparative  2−∆∆Ct 
method [62, 63]. PCR was performed at 50 °C for 2 min 
and at 95 °C for 20 s followed by 60 cycles of 5 s at 95 °C, 
20 s at 56 °C and 20 s at 65 °C.
B1‑LTR PCR for analysis of proviral integration
Briefly, a first stage PCR was run with a LTR forward 
primer, which was designed to harbor a lambda-phage 
heel sequence at the 5′ end and LTR sequences at the 3′ 
end. In addition, two outward facing primers binding the 
highly redundant consensus sequence within the mouse 
B1 repetitive element were used in the first stage PCR. 
This was followed by a second stage TaqMan-based quan-
titative real-time PCR, which amplified the LTR using 
a lambda-specific forward and an LTR-specific reverse 
primer, scored using an LTR-specific probe. Primer 
sequences and protocol were used from Tervo et al. [65]. 
For data analyses, genomic DNA from a SC-1 standard 
cell line, harboring three HIV-1-based vector integra-
tions [66], was diluted over a range of concentrations 
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covering three logs. Slope and y-intercept of the stand-
ard curve were used to determine proviral copies. PTBP2 
served as a housekeeping control. To exclude plasmid 
contamination of vector supernatants, 5 µM Nevirapine 
was used as an RT inhibitor, for every time point with 
equivalent volumes of vector supernatants, and signals 
were subtracted from the total signal. For each sample, 
PCR controls, omitting the B1 forward and reverse prim-
ers or the Lambda-LTR forward primer, were performed 
in parallel during the first PCR stage. The approach omit-
ting the Lambda-LTR forward primer did not reveal any 
signal. The signal achieved by omission of B1 forward 
and reverse primers was subtracted from the total signal 
for each sample.
Western blot analysis
Cells were harvested, washed with PBS and lysed by using 
radioimmunoprecipitation assay buffer supplemented 
with proteinase inhibitors (Complete Mini, Roche, Man-
nheim, Germany). Samples (15  µg) were separated by 
sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (12.5%) and blotted onto nitrocellulose membranes 
(GE Healthcare Europe GmbH). Antibody probing was 
conducted with rabbit monoclonal anti-CypA (Cell Sign-
aling Technology, Danvers, MA, USA) and rabbit poly-
clonal Erk2 (Santa Cruz Biotechnology) according to the 
manufacturer’s instructions. Goat anti-rabbit IgG con-
jugated with horseradish peroxidase was used as a sec-
ondary antibody. Quantitative detection was carried out 
using the Fusion Fx system (Peqlab GmbH/VWR Life 
Science Competence Center, Erlangen, Germany).
Pre‑transduction/abrogation experiments
iPSC were pre-transduced with LV.DsRed or GV.DsRed 
at an MOI of 1000. After spin-inoculation cells were 
incubated at 37  °C and 5%  CO2. After 6  h incubation 
time, iPSC were washed twice with PBS and a second 
transduction with LV was performed. LV encoding EGFP 
at an MOI of 100 were used for the second transduction. 
Flow cytometry analyses were conducted 4  days after 
transduction experiments.
Statistical analysis
Data were expressed as mean  ±  standard deviation. 
Where appropriate, we used one-way ANOVA with 
Tukey-Kramer post hoc test to adjust for multiplic-
ity effects. When comparing all groups to one control 
group, we utilized one-way ANOVA with Dunnett post 
hoc test. For time course analyses, we utilized repeated 
measures one-way ANOVA with appropriate post hoc 
test. The unpaired t test was performed for comparison 
of two groups. In case of significantly different variances 
between the groups, the unpaired t test with Welch’s 
correction was applied. p values of ≤  0.05 were consid-
ered significant (*), ≤  0.01 very significant (**), ≤  0.001 
extremely significant (***), and ns was considered not 
significant. Supplementary material and methods are 
described in Additional file 6.
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Additional files
 Additional file 1. MG132 exhibits cytotoxicity at doses ≥ 0.2 µM in iPSC. 
iPSC were treated with MG132 at indicated concentrations (n = 3). (A) Cell 
counts are shown after 12 hours. (B) Cells were stained for AnnexinV and 
PI after 12 hours and percentages of fluorescence positive cells are shown. 
Camptothecin served as a positive control for cytotoxicity.
Additional file 2. CSA exhibits no changes in cell growth or apoptosis at 
a concentration of 10 µM in iPSC. iPSC were treated with CSA at indicated 
concentrations and washed after 12 hours (n = 3). (A) Cell counts are 
shown after 48 hours. (B) Cells were stained for AnnexinV and PI after 48 
hours and percentages of fluorescence positive cells are shown. Campto-
thecin served as a positive control for cytotoxicity.
Additional file 3. iPSC transduced with wt or N74D capsid mutants 
exhibit comparable late RT levels. iPSC were transduced with LV N74D 
capsid mutant and wt at an MOI of 100. Late RT products were analyzed 
with TaqMan-based quantitative real-time PCR with  2−∆∆Ct method 24 
hours after transduction. Data are shown from 3 independent retroviral 
supernatants (n = 3) and as a ratio of late RT product level and plasmid 
contamination control, for which Nevirapine (Nev) was used, relative 
to endogenous PTBP2 level. The unpaired t-test was used for statistical 
analysis. ns p = 0.669.
Additional file 4. LV nuclear entry is impaired in iPSC. LV were applied to 
iPSC and CF-1 Mefs at an MOI of 100 in the presence of 10 µM CSA and/
or 50 µM Raltegravir or an equal volume of DMSO as solvent control. Data 
are shown from three independent retroviral supernatants (n = 3). (A) 
Relative 2-LTR circle levels were determined 48 hours after transduction 
and analyzed with TaqMan-based quantitative real-time PCR with the 
 2−∆∆Ct method, and normalized to endogenous PTBP2 copies. Data are 
shown relative to Mefs treated with DMSO. One-way ANOVA with Tukey-
Kramer post-hoc test was used for statistical analyses. ns p = 0.8338; ** 
p = 0.0013; *** p ≤ 0.001. (B) Relative vector copies were determined 21 
days after transduction and analyzed with TaqMan-based quantitative 
real-time PCR with the  2−∆∆Ct method, and normalized to endogenous 
PTBP2 copies. Data are shown relative to Mefs treated with DMSO. One-
way ANOVA with Tukey-Kramer post-hoc test was used for statistical 
analysis. *** p ≤ 0.001.
Additional file 5. Microarray analysis comparison of iPSC and fibroblasts 
reveals similar or even higher expression of a set of HIV-1 host co-factors 
and nucleoporins. Heat map is shown for 2 independent preparations of 
primary adult fibroblasts (Ad fib I + II), which served as parental fibroblasts 
for reprogramming, and different murine iPSC clones (#3, #2, #2EX). (A) 
 Log2-intensity values for important HIV-1 host co-factors for nuclear entry 
and integration. (B)  Log2-intensity values for a set of murine nucleoporins.
Additional file 6. Supplementary material and methods.
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